The trial showed PD-L1 IHC 22C3 expression in at least 50% of tumor cells was correlated with improved response, which led to the initial FDA approval of pembrolizumab monotherapy in the NSCLC second-line treatment setting. The gene discussed is CD274; the disease is neoplasm.